Navigation Links
Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
Date:7/26/2010

EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.  In an independent review of the data, carfilzomib achieved an overall response rate (partial response or greater) of 24 percent and a median duration of response of 7.4 months in patients who entered the study after receiving a median of five prior lines of therapy (corresponding to a median of 13 anti-myeloma agents) and whose disease was refractory to their last therapeutic regimen. The clinical benefit rate (minimal response or greater) in the study population was 36 percent.  Carfilzomib was well-tolerated and there were no new or unexpected toxicities observed.  Full results of the trial will be presented at an upcoming scientific meeting.  Based on these results, Onyx is continuing discussions with the U.S. Food and Drug Administration (FDA) regarding next steps in filing a new drug application (NDA) for carfilzomib, which the company expects to submit by year-end 2010 for potential accelerated approval in the U.S.

"Despite recent advances in treating multiple myeloma, all patients eventually relapse. The unmet medical need remains great, as the outlook for patients with relapsed and refractory disease is grim," said Michael G. Kauffman, M.D., Ph.D., Chief Medical Officer of Onyx Pharmaceuticals. "According to a study from the International Myeloma Working Group, patients, such as those enrolled in the 003-A1 study, can expect to respond to therapy only 11 percent of the time and survive f
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
2. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
3. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
4. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
5. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
6. Lotus Pharmaceuticals Terminates SEDA
7. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
8. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
9. Endo Pharmaceuticals to Announce Second Quarter 2010 Financial Results on July 30, 2010
10. Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector
11. Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... Dilon expands its portfolio of breast imaging solutions ... Mammography Information System technology by KLAS for three ... loyalty are the foundation of PenRad,s success. Together ... and an information management system that significantly improves ...
... Hurricane Irene came rushing up the East Coast as a ... United States, many states in the Northeast began to worry. The ... hurricanes. Coastal towns from New Jersey all the way up to ... City was one that took steps that had not been seen ...
Cached Medicine Technology:Dilon Diagnostics® Partners With PenRad® 2Dilon Diagnostics® Partners With PenRad® 3Hospitals Evacuated in Preparation for Hurricane Irene with Aid of Pulse Oximeter 2
(Date:7/30/2014)... York, New York (PRWEB) July 30, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to ... added her voice to those calling for a ban ... in Denver, Debra Valverde was diagnosed with leiomyosarcoma following ... morcellator. Within a year of her diagnosis, the aggressive ...
(Date:7/30/2014)... Hospitals continually face the challenge of ... their practitioners provide. During a recent AllMed webinar, ... importance of establishing effective peer review practitioner evaluation ... of care. , With regard to best ... on setting performance expectations, conducting regular evaluations, maintaining ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 ... China Chitosan Industry” is a professional and ... market. The report provides basic Chitosan information, ... chain structure as well as industry overview. ... China’s domestic market as well as global ...
(Date:7/30/2014)... -- For patients with asthma, just believing an odor ... for at least 24 hours, a new study indicates. ... what you think you smell," study author Cristina Jaen, ... said in a Monell news release. "Asthmatics ... expect that an odor is harmful, our bodies react ...
(Date:7/30/2014)... the many sub-groups of cells jockeying for supremacy within ... those that can proliferate the fastest, researchers at Dana-Farber ... advance online publication of the journal Nature . ... of cancer with precision medicines, the study authors explained: ... driving the tumor,s growth and metastasis and select drugs ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3
... safer glucocorticoid drugs , Glucocorticoid drugs are ... allergic reactions, asthma, and some forms of cancer, and ... their potent antiinflammatory and immunosuppressive properties. However, their long-term ... blood levels of glucose, fatty liver, and type 2 ...
... , This release is available in French ... and the brain appear to be even more closely connected ... apparently not confined to the heart, but also affect the ... the level of the brainstem, which leads to insomnia, notably ...
... be the victim of a snakebite, the best thing you ... possible, according to a new review article from the ... Current medical treatments, including new medications and surgery, if necessary, ... do on your own. , "Previous generations of antivenin medications ...
... risk of prostate cancer, a new study published today in the ... led by The University of Warwick and The Institute of Cancer ... ring finger were one third less likely to develop the disease ... show that relative finger length could be used as a simple ...
... 2010 Elsevier, the leading publisher of scientific, technical ... availability of Case Reviews Online, an online edition of ... for board review. The Case Reviews Online ... board preparation needs. Detailed cases, including 4-10 images ...
... Eating a diet rich in omega-3 fatty acids appears to ... known as age-related macular degeneration (AMD), a new analysis indicates. ... and shellfish may protect against advanced AMD," study lead author ... Hopkins School of Medicine in Baltimore, said in a news ...
Cached Medicine News:Health News:JCI online early table of contents: Dec. 1, 2010 2Health News:JCI online early table of contents: Dec. 1, 2010 3Health News:JCI online early table of contents: Dec. 1, 2010 4Health News:JCI online early table of contents: Dec. 1, 2010 5Health News:JCI online early table of contents: Dec. 1, 2010 6Health News:JCI online early table of contents: Dec. 1, 2010 7Health News:JCI online early table of contents: Dec. 1, 2010 8Health News:JCI online early table of contents: Dec. 1, 2010 9Health News:JCI online early table of contents: Dec. 1, 2010 10Health News:Insomnia after myocardial infarction 2Health News:What to do if you are bitten by a snake 2Health News:Finger length points to prostate cancer risk 2Health News:Elsevier launches innovative online radiology board review product 2Health News:Can Omega-3 Foods Prevent Eye Disease in Seniors? 2
... premium product for acne, XtremeClear, powered ... on a scalable multi-application platform. A ... acne, XtremeClear works fast, providing noticeable ... treatments. Uncompromising safety in each of ...
... SpaTouch was designed specifically to meet the varying ... is a simple to use, compact, dual application ... lucrative field of light based hair removal. SpaTouch ... is safe for use on nearly all face ...
... all of the benefits and functionality ... the additional feature of being able ... scanner for importing and storage of ... images. This additional feature allows for ...
Inquire...
Medicine Products: